Your browser is no longer supported. Please, upgrade your browser.
Settings
EYEN Eyenovia, Inc. daily Stock Chart
EYEN [NASD]
Eyenovia, Inc.
Index- P/E- EPS (ttm)-1.16 Insider Own27.30% Shs Outstand19.82M Perf Week1.69%
Market Cap85.43M Forward P/E- EPS next Y-0.93 Insider Trans17.50% Shs Float13.77M Perf Month13.12%
Income-20.40M PEG- EPS next Q-0.18 Inst Own5.60% Short Float0.49% Perf Quarter-2.43%
Sales- P/S- EPS this Y19.00% Inst Trans1.46% Short Ratio0.06 Perf Half Y1.40%
Book/sh0.42 P/B8.62 EPS next Y-3.10% ROA-135.90% Target Price- Perf Year13.12%
Cash/sh0.43 P/C8.38 EPS next 5Y- ROE-166.90% 52W Range1.11 - 6.92 Perf YTD-19.20%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-51.45% Beta-
Dividend %- Quick Ratio4.00 Sales past 5Y- Gross Margin- 52W Low202.70% ATR0.22
Employees27 Current Ratio4.00 Sales Q/Q- Oper. Margin- RSI (14)45.72 Volatility5.48% 6.00%
OptionableNo Debt/Eq0.08 EPS Q/Q42.90% Profit Margin- Rel Volume0.12 Prev Close3.62
ShortableYes LT Debt/Eq0.04 EarningsAug 12 AMC Payout- Avg Volume1.20M Price3.36
Recom1.70 SMA20-2.90% SMA50-3.02% SMA200-1.83% Volume145,435 Change-7.18%
Feb-03-20Downgrade Oppenheimer Outperform → Perform
Oct-13-20 03:40PM  
07:00AM  
Oct-12-20 07:00AM  
Oct-05-20 07:00AM  
Sep-09-20 08:30AM  
Aug-26-20 07:31AM  
Aug-24-20 08:30AM  
Aug-21-20 04:05PM  
Aug-19-20 09:10AM  
Aug-18-20 04:03PM  
Aug-12-20 04:05PM  
07:29AM  
Aug-11-20 08:00AM  
Jul-29-20 08:30AM  
Jul-20-20 03:30PM  
Jun-30-20 04:05PM  
Jun-11-20 04:10PM  
Jun-05-20 04:10PM  
May-13-20 04:05PM  
May-06-20 08:30AM  
Apr-22-20 10:10AM  
Mar-26-20 06:31AM  
Mar-25-20 04:05PM  
02:30PM  
Mar-24-20 05:10PM  
Mar-23-20 06:35PM  
Mar-11-20 08:30AM  
Mar-04-20 08:30AM  
Feb-17-20 07:33AM  
Feb-10-20 09:25AM  
Dec-19-19 09:55AM  
08:30AM  
Dec-02-19 09:02AM  
Nov-27-19 09:00AM  
Nov-13-19 04:05PM  
Nov-12-19 10:42AM  
08:23AM  
Nov-11-19 11:24AM  
09:42AM  
07:50AM  
Nov-07-19 11:15AM  
10:32AM  
Nov-06-19 09:56AM  
Nov-05-19 11:50AM  
11:24AM  
11:13AM  
Nov-04-19 11:42AM  
10:56AM  
10:49AM  
10:22AM  
10:01AM  
09:10AM  
Oct-31-19 10:47AM  
08:30AM  
Oct-30-19 07:01AM  
Oct-29-19 04:05PM  
Oct-02-19 08:30AM  
Sep-19-19 12:07PM  
Sep-03-19 08:30AM  
Aug-12-19 02:30PM  
Aug-06-19 08:30AM  
Jul-16-19 04:05PM  
Jul-15-19 07:15PM  
04:30PM  
Jul-11-19 11:13AM  
09:00AM  
Jul-10-19 04:07PM  
Jun-04-19 08:30AM  
May-14-19 06:30AM  
May-06-19 10:53AM  
May-01-19 08:30AM  
Mar-27-19 06:30AM  
Mar-13-19 08:30AM  
Mar-04-19 08:30AM  
Feb-25-19 08:30AM  
Feb-13-19 08:30AM  
Feb-06-19 08:30AM  
Feb-05-19 08:00AM  
Jan-31-19 08:30AM  
Jan-30-19 09:35AM  
07:56AM  
07:00AM  
Dec-25-18 01:39PM  
Dec-19-18 02:45PM  
09:05AM  
Dec-03-18 09:00AM  
Nov-28-18 04:05PM  
Nov-27-18 10:44AM  
07:32AM  
Nov-26-18 05:26PM  
09:00AM  
Nov-21-18 08:50AM  
Nov-13-18 07:30AM  
06:30AM  
Nov-01-18 08:30AM  
Oct-23-18 09:00AM  
Oct-05-18 08:01PM  
Sep-24-18 07:22PM  
Sep-19-18 08:30AM  
Sep-18-18 07:30AM  
Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet. It focuses on achieving clinical microdosing of next-generation formulations of ophthalmic pharmaceutical agents using its ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. The company, through its proprietary delivery technology, is developing smart ophthalmic therapies while targeting new indications for which there are currently no drug therapies approved by the U.S. Food and Drug Administration. Eyenovia, Inc. focuses on advancing its MicroLine program for the improvement in near vision in patients with presbyopia in Phase III development. Its other product candidates include MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma, open angle glaucoma, and ocular hypertension; MicroStat, which has completed Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of red eye and itch relief lubrication; and MicroPine for the treatment of progressive myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grant Stuart M.10% OwnerOct 12Buy3.55100,000355,0004,219,748Oct 13 11:54 AM
Grant Stuart M.10% OwnerSep 24Buy2.9975,000224,5004,119,748Sep 25 01:42 PM
Clasby Jennifer GVP, Clinical OperationsSep 18Option Exercise1.9526,73752,13755,702Oct 16 05:04 PM
Grant Stuart M.10% OwnerAug 20Buy2.06451,620929,4344,044,748Aug 24 06:05 AM
Grant Stuart M.10% OwnerAug 19Buy3.60333,0001,198,8003,593,128Aug 24 06:05 AM
MARIO ERNESTDirectorMar 24Buy2.2782,431187,118327,239Mar 26 06:12 PM
Ianchulev TsontchoChief Executive OfficerMar 24Buy2.2782,431187,118508,679Mar 26 06:17 PM
Grant Stuart M.10% OwnerMar 23Buy2.06903,2401,858,8683,260,128Mar 25 05:51 PM
Grant Stuart M.10% OwnerNov 13Buy2.6510,00026,5002,356,888Nov 18 06:01 AM
Grant Stuart M.10% OwnerNov 12Buy2.7029,94580,7622,346,888Nov 18 06:01 AM
Grant Stuart M.10% OwnerOct 31Buy2.716,07216,4492,316,943Nov 18 06:01 AM
Grant Stuart M.10% OwnerOct 30Buy2.8525,00071,3502,310,871Nov 18 06:01 AM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.